Drug Trial Radar · NCT05985707
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 15, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Peking University Cancer Hospital & InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 (a PD-L1/CTLA-4 targeted bispecific antibody).
Conditions
- HER2-positive Colorectal Cancer
- HER2-positive Biliary Tract Cancer
Interventions
KN026Drug
KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
KN046Drug
KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
XELOXDrug
XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rateTime frame: Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 24 months post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University cancer hospital & institution
Beijing, State*, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.